Verition Fund Management LLC Aim Immuno Tech Inc. Transaction History

Verition Fund Management LLC

$13 Billion
Q1 2024

A detailed history of Verition Fund Management LLC transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 171,000 shares of AIM stock, worth $64,980. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171,000

Previous 162,000 5.56%

Holding current value

$64,980

Previous $71,000 12.68%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$0.33 - $0.48 $2,970 - $4,320	9,000 Added 5.56%	171,000 $80,000
Q4 2023 Feb 14, 2024	BUY	$0.4 - $0.56 $5,600 - $7,840	14,000 Added 9.46%	162,000 $71,000
Q3 2023 Nov 14, 2023	BUY	$0.44 - $0.71 $3,520 - $5,680	8,000 Added 5.71%	148,000 $68,000
Q2 2023 Aug 14, 2023	SELL	$0.4 - $0.67 $1,600 - $2,680	-4,000 Reduced 2.78%	140,000 $93,000
Q1 2023 May 15, 2023	SELL	$0.32 - $0.77 $2,880 - $6,930	-9,000 Reduced 5.88%	144,000 $61,000

Q4 2022 Feb 14, 2023	SELL	$0.31 - $0.6 $0 - $1	-2 Reduced -0.0%	153,000 $47,000
Q2 2022 Aug 15, 2022	BUY	$0.78 - $1.27 $1 - $2	2 Added 0.0%	153,002 $119,000
Q1 2022 May 13, 2022	SELL	$0.67 - $1.18 $6,030 - $10,620	-9,000 Reduced 5.56%	153,000 $162,000
Q4 2021 Feb 14, 2022	BUY	$0.92 - $1.96 $12,439 - $26,501	13,521 Added 9.11%	162,000 $149,000
Q3 2021 Nov 15, 2021	BUY	$1.91 - $2.17 $77,314 - $87,839	40,479 Added 37.48%	148,479 $300,000
Q1 2021 May 18, 2021	BUY	$1.88 - $2.82 $90,240 - $135,360	48,000 Added 80.0%	108,000 $245,000
Q4 2020 Feb 16, 2021	BUY	$1.68 - $2.45 $33,600 - $49,000	20,000 Added 50.0%	60,000 $107,000
Q3 2020 Nov 16, 2020	BUY	$1.77 - $3.88 $70,800 - $155,200	40,000 New	40,000 $86,000

Others Institutions Holding AIM

# of Institutions

Shares Held

4.09M

Call Options Held

Put Options Held

View Full List

About AIM ImmunoTech Inc.

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $18.3M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

More about AIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.

Account

Verition Fund Management LLC Aim Immuno Tech Inc. Transaction History